Baigent C.Landray M.Reith C.Dasgupta T.Emberson J.Herrington W.Lewis D.Mafham M.Collins R.Bray C.Chen Y.Baxter A.Young A.Hill M.Knott C.Cass A.TING TSE LIN2023-04-122023-04-122010-11-010002-8703https://scholars.lib.ntu.edu.tw/handle/123456789/630142Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people with chronic kidney disease (CKD).enREQUIRING PROLONGED OBSERVATIONUNITED-KINGDOM HEARTCARDIOVASCULAR OUTCOMESsimvastatinefficacyEZETIMIBEdesignstatinssafety[SDGs]SDG3journal article10.1016/j.ahj.2010.08.012210952632-s2.0-78650184434WOS:000284458700003https://api.elsevier.com/content/abstract/scopus_id/78650184434